Last reviewed · How we verify
SM-1
SM-1 is a small molecule that targets the PD-1 receptor.
SM-1 is a small molecule that targets the PD-1 receptor. Used for Metastatic non-small cell lung cancer, PD-L1 positive, Metastatic melanoma.
At a glance
| Generic name | SM-1 |
|---|---|
| Sponsor | Sequential Medicine Ltd |
| Drug class | PD-1 inhibitor |
| Target | PD-1 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
SM-1 works by binding to the PD-1 receptor, preventing its interaction with its ligand PD-L1, and thereby enhancing T-cell activation and proliferation. This leads to an increase in anti-tumor immune response.
Approved indications
- Metastatic non-small cell lung cancer, PD-L1 positive
- Metastatic melanoma
Common side effects
- Pneumonitis
- Hypothyroidism
- Diarrhea
Key clinical trials
- Multicenter Cohort Study of ESD and Chemo-radiotherapy for High-risk Early-stage Esophageal Cancer
- An Investigational Study to Assess Efficacy and Pattern of Use of SM-1 in Subjects With a History of Transient Insomnia (PHASE3)
- Multicenter Observational Study Taulí-T1 Classification for the Management of pT1 Rectal Adenocarcinoma
- Non-invasive Brain Stimulation to Enhance Treatment of Dysarthria Post-stroke (NA)
- Non-invasive Brain Stimulation as a Treatment for Dysarthria Post-stroke (NA)
- PEaters Choice™: Nutrition Intervention Module for Picky Eaters (NA)
- SM-1 vs. an Active Comparator in A Model of Transient Insomnia (PHASE2)
- SM-1 vs 2 Comparators and Placebo in Participants With a History of Transient Insomnia. (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |